Directed induction of alveolar type I cells derived from pluripotent stem cells via Wnt signaling inhibition.


Journal

Stem cells (Dayton, Ohio)
ISSN: 1549-4918
Titre abrégé: Stem Cells
Pays: England
ID NLM: 9304532

Informations de publication

Date de publication:
02 2021
Historique:
received: 23 03 2020
accepted: 31 10 2020
pubmed: 27 11 2020
medline: 15 12 2021
entrez: 26 11 2020
Statut: ppublish

Résumé

Alveologenesis is a developmental step involving the expansion of the lung surface area which is essential for gas exchange. The gas exchange process is mediated by alveolar type I (AT1) cells, which are known to be differentiated from alveolar type II (AT2) or bipotent cells. Due to the difficulty of isolating and culturing primary AT1 cells, the mechanism underlying their differentiation is not completely understood. We performed single-cell RNA sequencing (scRNA-seq) of fibroblast-dependent alveolar organoids (FD-AOs), including human induced pluripotent stem cell (hiPSC)-derived epithelial cells and fetal lung fibroblasts, and identified hiPSC-derived AT1 (iAT1) cells. A comparison of the FD-AOs and fibroblast-free alveolar organoids showed that iAT1 cells were mainly present in the FD-AOs. Importantly, the transcriptomes of iAT1 cells were remarkably similar to those of primary AT1 cells. Additionally, XAV-939, a tankyrase inhibitor, increased iAT1 cells in passaged FD-AOs, suggesting that these cells were differentiated from hiPSC-derived AT2 (iAT2) cells through the inhibition of canonical Wnt signaling. Consequently, our scRNA-seq data allowed us to define iAT1 cells and identify FD-AOs as a useful model for investigating the mechanism underlying human AT1 cell differentiation from AT2 cells in vitro.

Identifiants

pubmed: 33241896
doi: 10.1002/stem.3302
pmc: PMC7898721
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

156-169

Informations de copyright

© 2020 The Authors. STEM CELLS published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Références

Am J Respir Cell Mol Biol. 2017 Mar;56(3):310-321
pubmed: 27749084
Cell Stem Cell. 2017 Oct 5;21(4):472-488.e10
pubmed: 28965766
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nature. 2014 Mar 13;507(7491):190-4
pubmed: 24499815
Stem Cell Reports. 2014 Sep 9;3(3):394-403
pubmed: 25241738
Nature. 2018 Mar 8;555(7695):251-255
pubmed: 29489752
PLoS Genet. 2013 Jun;9(6):e1003513
pubmed: 23818859
Nature. 2014 May 15;509(7500):371-5
pubmed: 24739965
Stem Cells. 2021 Feb;39(2):156-169
pubmed: 33241896
Cell Stem Cell. 2020 Apr 2;26(4):593-608.e8
pubmed: 32004478
J Clin Invest. 2013 Jul;123(7):3025-36
pubmed: 23921127
Cell Rep. 2016 Nov 22;17(9):2312-2325
pubmed: 27880906
J Clin Invest. 2020 Jan 2;130(1):157-170
pubmed: 31550239
Am J Physiol Cell Physiol. 2014 Aug 1;307(3):C234-44
pubmed: 24898581
Nat Biotechnol. 2020 Dec;38(12):1408-1414
pubmed: 32747759
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20545-20555
pubmed: 31548395
Am J Physiol. 1998 Jul;275(1):L155-64
pubmed: 9688947
Nat Commun. 2015 Apr 13;6:6727
pubmed: 25865356
Nat Methods. 2017 Nov;14(11):1097-1106
pubmed: 28967890
Stem Cell Reports. 2019 Mar 5;12(3):431-440
pubmed: 30773483
J Clin Invest. 2013 Nov;123(11):4950-62
pubmed: 24135142
Nat Cell Biol. 2020 Aug;22(8):934-946
pubmed: 32661339
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2407-2412
pubmed: 29463737
Dev Cell. 2020 Mar 9;52(5):617-630.e6
pubmed: 32059772
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
JCI Insight. 2016 Dec 8;1(20):e90558
pubmed: 27942595
Science. 2018 Mar 9;359(6380):1118-1123
pubmed: 29420258

Auteurs

Shuhei Kanagaki (S)

Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Satoshi Ikeo (S)

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Takahiro Suezawa (T)

Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yuki Yamamoto (Y)

Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Masahide Seki (M)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Toyohiro Hirai (T)

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Masatoshi Hagiwara (M)

Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yutaka Suzuki (Y)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Shimpei Gotoh (S)

Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH